# An Extension to Study MA21573, Evaluating Tocilizumab in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biological DMARDs and/or Anti-tumor Necrosis Factor (TNF) Therapy

> **NCT00883753** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 934 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** tocilizumab [RoActemra/Actemra]

## Key facts

- **NCT ID:** NCT00883753
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-03
- **Primary completion:** 2012-04
- **Final completion:** 2012-04
- **Target enrollment:** 934 (ACTUAL)
- **Last updated:** 2014-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00883753

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00883753, "An Extension to Study MA21573, Evaluating Tocilizumab in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biological DMARDs and/or Anti-tumor Necrosis Factor (TNF) Therapy". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT00883753. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*